Blog

Allan Galper

Allan Galper is Vice President & Associate General Counsel at Fidelity Investments and supports the F-Prime team on legal aspects of the firm’s operations, including portfolio company investments and exits, fund formation, ongoing fund administration, and day-to-day management company operations.

Allan joined Fidelity in 2012 from McCarter & English, where he was a Partner and a member of the Corporate, Securities and Business Transactions Practice Group. Allan also previously worked as an associate in the Corporate Department of the international law firm Willkie Farr & Gallagher. He has over 25 years of legal experience counseling venture capital and private equity firms, public and private companies, and entrepreneurs on a variety of matters, including company formation, equity and debt financings, mergers and acquisitions, strategic alliances, public offerings, securities law matters, corporate governance, bank credit facilities, intellectual-property transactions, employment matters, and other general business matters. Over the course of his career, Allan has worked across a broad spectrum of industries, including biotechnology, health care, medical devices, pharmaceuticals, software, internet, information technology and financial services.

Allan received his B.A., magna cum laude, from Harvard University and his J.D. from Fordham Law School, where he was an Associate Editor of the Fordham International Law Journal.

Allan is admitted to the Massachusetts and New York bars.

Sarah Alvarez

Sarah Alvarez joined F-Prime in February, 2016. She is the Executive Assistant to Ketan Patel and Gaurav Tuli. Prior to F-Prime, Sarah worked as a Human Resources Assistant at Biogen for three years. Sarah attended the University of Massachusetts, Amherst with a concentration in Psychology. 

Laura Wysk

Laura Wysk joined F-Prime in August of 2014. She is the Executive Assistant to Jon Lim, Carolyn Haley, M.S., CPA, Carl Byers, and supports the Operations team initiatives. Previously, she worked for Partners Healthcare at Mass General Hospital for eight years. Laura received her BA in Communications & Film from the University of Massachusetts, Amherst.

Ben Gorman

Ben Gorman is a Principal at F-Prime, where he focuses on early-stage investments in enterprise software and AI. Prior to joining F-Prime, he was a managing consultant at IBM, providing internal strategy and analytics consulting to IBM’s business units and geographies. The primary focus of his work was transforming the company’s go-to-market to better leverage data and ML.

Ben is a graduate of Carnegie Mellon University, where he studied Statistics and Economics. He is an avid mountaineer and has summitted the highest peak on three continents in addition to completing many alpine climbs and ski descents in the mountain west.

Gaurav Tuli

Gaurav is a Partner at F-Prime where he focuses on enterprise technology investing. He has led F-Prime investments in Threat Stack (acquired by F5 Networks), RiskRecon (acquired by Mastercard), Protenus (acquired by Bluesight), Risklens (acquired by Safe Security), Lighthouse, Canary Technologies, Funnel, Warmly, Deal Engine, and many others. Prior to F-Prime, Gaurav was a Principal at F-Prime’s sister fund, Eight Roads Ventures Europe, based in London, where he invested in European software and online services businesses and served on the boards of Appsflyer and Neo4j. Previously, Gaurav was a product portfolio manager at EMC’s largest business unit, Symmetrix. Gaurav was a computer scientist by training and spent the early parts of his career at Credit Suisse and McKinsey and Company.

Gaurav attended MIT for his bachelors and masters degrees in computer science, as well as his MBA.

Sanjay Aggarwal

Sanjay Aggarwal is a Venture Partner focused on physical and enterprise AI opportunities. His investments include Seyond (IPO on HKEX), Securonix (acquired by Vista Equity), Mineral Tree (acquired by Global Payments), Snapsheet, MoEngage, Whatfix, Burro, Teleo, Unbox Robotics, and RightHand Robotics. Prior to joining F-Prime, Sanjay was CEO of Unicel Technologies, an India-focused mobile messaging company, which was acquired by Karix Mobile.

Earlier in his career, Sanjay worked at Devonshire Investors (the private equity group of Fidelity Investments), McKinsey and Company in their US and India offices, and at Berkeley Process Control (acquired by Moog Inc), where he built machine automation systems. Sanjay holds a B.S. in Mechanical Engineering from MIT, an M.S. in Mechanical Engineering from UC Berkeley, and an M.B.A. from the MIT Sloan School of Management.

Chong Xu, PhD

Chong Xu is a Partner at F-Prime. He focuses primarily on biopharmaceutical and medical technology sectors. He also works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China. At F-Prime, Chong has been involved in a number of company formations including as a founding investor of AlphaGen Tx, Pediatrix, Skyline Tx, K36 Tx, and RareStone Group. Other companies Chong holds or has held board positions also include OnCusp Tx, Remunix, Shinobi Tx, Sironax, Semma Tx, Adagene, Innovent, etc. Prior to joining F-Prime in 2015, Chong was a management consultant at McKinsey and Company, a hedge fund healthcare equity analyst at Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a PhD in Cell Biology from University of Virginia and a MBA from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

Jessica Alston, PhD

Jessica is a Partner at F-Prime and focuses primarily on the biopharmaceutical and medical technology sectors. Prior to joining F-Prime in 2015, Jessica was an engagement manager in McKinsey and Company’s Boston office, where she focused on pharmaceuticals and medical products and advised companies across a range of strategic, organizational, and operational topics. She began her career at MIT Lincoln Laboratory in the Biodefense Systems group, where she worked on developing novel techniques for the detection of biological agents.

Jessica holds a PhD in genetics from Harvard University and received her BS in biology from Duke University.

Stacie Weninger, PhD

Stacie Weninger, PhD, is a Venture Partner with F-Prime. She is a neuroscientist, biotech leader, and investor with more than 20 years of experience building, advising, and backing innovative neuroscience companies. She focuses on advancing neuroscience research and early-stage therapeutics through strategic collaboration, investment, and advisory roles, helping translate early scientific discoveries into novel medicines and build enduring companies.

Dr. Weninger served as President of the F-Prime Biomedical Research Initiative (FBRI), where she helped catalyze academic–industry collaboration and advance early neuroscience research toward therapeutic development.

Dr. Weninger currently serves as CEO and Chairman of the Board of Directors of Rugen Therapeutics and serves on the Boards of Aratome, Atalanta, Engrail, and Tenvie Therapeutics. She was a founding member of the Boards of Directors of Denali Therapeutics (NASDAQ: DNLI) and Neumora Therapeutics (NASDAQ: NMRA) and has held Board roles at numerous companies, including Annexon Biosciences (NASDAQ: ANNX), BRI-Alzan (acquired by MeiraGTx), Digital Cognition Technologies (acquired by Linus Health), Enspectra, Inscopix (acquired by Bruker Corporation), and Sironax.

In addition to her work in company creation and biotech investing, Dr. Weninger holds leadership and advisory roles across the neuroscience ecosystem. She serves on the Board of Target ALS, the Governing Board of the Michael J. Fox Foundation’s Targets to Therapeutics Initiative, and is a member of the Harvard Experts in Residence (XIR) network. Dr. Weninger is a member of numerous Scientific Advisory Boards, including those of Denali Therapeutics, the Breuer Foundation, Brown University’s Carney Center for Alzheimer’s Disease Research, the Harvard Blavatnik Biomedical Accelerator Fund, the Indian Institute of Science’s Centre for Brain Research, MIT’s Yang–Tan Center for Molecular Therapeutics, the External Advisory Board of Boston Children’s Hospital’s Rosamund Stone Zander Translational Neuroscience Center, and the UK Dementia Research Institute, among others. She also chairs the Collaboration for Alzheimer’s Prevention, which focuses on sharing learnings and best practices to accelerate clinical trials in early-stage Alzheimer’s disease. She previously served as President of Alzforum for more than a decade and continues as a special advisor.

Prior to joining F-Prime, Dr. Weninger was Senior Director of Science Programs at the Fidelity Foundations, where she oversaw biomedical research funding initiatives. Earlier in her career, she served as Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University and was a Senior Scientific Editor at Neuron (Cell Press). She began her scientific career as a postdoctoral research fellow in Dr. Bruce Yankner’s laboratory at Boston Children’s Hospital and Harvard Medical School.

Dr. Weninger received her PhD in neuroscience from Harvard University as a Howard Hughes Medical Institute predoctoral fellow and earned a B.S. in chemistry with highest honors from the University of North Carolina at Chapel Hill.

Kevin Chu

Kevin Chu joined F-Prime in 2014 and is currently a Principal on the healthcare investment team based in San Francisco. Prior to F-Prime, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy.

At F-Prime, Kevin focuses primarily on investments in therapeutics, medical devices, and life science tools companies. He was a member of the founding team at Shinobi Therapeutics, led the fund’s investments in Apreo Health, Amber Therapeutics, Cadence Neuroscience and was involved with several legacy fund investments including Innovent Biologics (1801.HK), Semma Therapeutics (acquired by Vertex), Modis Therapeutics (acquired by Zogenix), Farapulse (acquired by Boston Scientific), Cytek Biosciences (NASDAQ: CTKB), and Sipai Health Technology (0314.HK). He also works closely with the Eight Roads Ventures China team to manage F-Prime’s healthcare investment efforts in China.

Kevin holds a B.S.E. from the University of Pennsylvania where he studied Bioengineering and Engineering Entrepreneurship.